Unusual global outbreak of monkeypox: what should we do?

Front Med

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.

Published: August 2022

AI Article Synopsis

  • - Recent outbreaks of monkeypox have raised global concerns, particularly during the ongoing COVID-19 pandemic, as the virus has spread beyond its usual regions in Africa into nonendemic countries with person-to-person transmission.
  • - This review outlines essential information regarding monkeypox, including its epidemiology, biological aspects, disease progression, clinical signs, and available treatments and vaccines.
  • - The article emphasizes the need for proactive measures, drawing on current research and clinical insights to manage and mitigate the unusual outbreak and prevent further escalation of the situation.

Article Abstract

Recently, monkeypox has become a global concern amid the ongoing COVID-19 pandemic. Monkeypox is an acute rash zoonosis caused by the monkeypox virus, which was previously concentrated in Africa. The re-emergence of this pathogen seems unusual on account of outbreaks in multiple nonendemic countries and the incline to spread from person to person. We need to revisit this virus to prevent the epidemic from getting worse. In this review, we comprehensively summarize studies on monkeypox, including its epidemiology, biological characteristics, pathogenesis, and clinical characteristics, as well as therapeutics and vaccines, highlighting its unusual outbreak attributed to the transformation of transmission. We also analyze the present situation and put forward countermeasures from both clinical and scientific research to address it.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362077PMC
http://dx.doi.org/10.1007/s11684-022-0952-zDOI Listing

Publication Analysis

Top Keywords

monkeypox
5
unusual global
4
global outbreak
4
outbreak monkeypox
4
monkeypox do?
4
do? monkeypox
4
monkeypox global
4
global concern
4
concern amid
4
amid ongoing
4

Similar Publications

Heterologous protein expression often faces significant challenges, particularly when the target protein has posttranslational modifications, is toxic, or is prone to misfolding. These issues can result in low expression levels, aggregation, or even cell death. Such problems are exemplified by the expression of phospholipase p37, a critical target for chemotherapeutic drugs against pathogenic human orthopoxviruses, including monkeypox and smallpox viruses.

View Article and Find Full Text PDF

To address the issues of infectious virus, bacterial secondary infections, skin pigmentation, and scarring caused by monkeypox virus (MPXV), a sprayable hydrogel with versatile functions was developed with comprehensive properties. Based on current research, the bioactive deep eutectic solvent (DES) of rosmarinic acid-proanthocyanidin-glycol (RPG) was designed and synthesized as active agent, and molecular docking was applied to discover its binding to MPXV proteins through H-bonds and van der Waals interactions, and the docking results show the binding energies between RA, PC, Gly and MPXV proteins are -58.7188, -50.

View Article and Find Full Text PDF

Monkeypox (mpox), caused by the MPOXV (monkeypox virus), has been endemic in Africa since its first identification in 1958. However, in May 2022, the world witnessed the first global outbreak associated with the West African clade. Even though thousands of cases have been recorded, our understanding of vertical transmission during pregnancy remains restricted due to an absence of reported cases in pregnant women and a lack of adequate clinical descriptions.

View Article and Find Full Text PDF

The outbreak of clade II monkeypox virus (MPXV) and the additional outbreak in Central Africa of clade I virus from 2023 have attracted worldwide attention. The development of a scalable and effective vaccine against the ongoing epidemic of mpox is urgently needed. We previously constructed two bivalent MPXV mRNA vaccines, LBA (B6R-A29L) and LAM (A35R-M1R), and a quadrivalent mRNA vaccine, LBAAM (B6R-A35R-A29L-M1R).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!